Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ:OCUL) has granted a non-statutory stock option for 350,000 shares of common stock to new employee Philip C. Strassburger to incentivize his employment commencement. The option, effective October 5, 2020, has an exercise price of $8.42 per share, matching the closing stock price on that date. It features a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was independently approved by Ocular's Compensation Committee.